|
Thursday, 01 November 2007 |
|
Forest Laboratories, Inc.
today announced the results of a double-blind, randomized,
placebo-controlled clinical trial which demonstrated that nebivolol
significantly reduced sitting diastolic and systolic blood pressure used as
monotherapy among African-American patients with stage I-II hypertension. The
study also found that nebivolol was well tolerated in comparison to placebo,
with a low incidence of traditional beta blocker side effects, such as
fatigue, sexual dysfunction, and depression.
|